ASX small-cap AusCann Group ramps up cannabis research

Cannabis-related research and development is booming at the moment as companies rush to capitalise on its gradual legalisation.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cannabis-related research and development is booming at the moment as companies rush to capitalise on its gradual legalisation.

AusCann Group Holdings Ltd (ASX: AC8) has established a Perth R&D facility in a $5.25m acquisition that it hopes will strengthen its product pipeline. The site will focus on the development of 'innovative formulations and dose forms' for pharmaceutical applications.

The move shows AusCann is making moves to bolster its pharmaceutical development program, which it says sets itself apart from other Australian cannabis producers.

Fully funded by cash-on-hand, the facility will also require an additional $6 million of capital investment to get it up and running by the end of the year.

AusCann interim CEO, Dr Paul MacLeman said: 'The acquisition of the research and development site is a major stepping stone for AusCann as it allows the creation of a fully integrated, state of the art facility for medicinal cannabis.'

The company is also gearing up for the launch of its hard-shell cannabinoid capsules this year, with production planned to begin in the middle of the year.

Meanwhile, medical dermatology company Botanix Pharmaceuticals Ltd (ASX: BOT) is also making headway on its clinical study for the treatment of atopic dermatitis with its BTX1204 product.

Botanix focuses on the application of cannabidiol for pharmaceutical applications. The company currently has four products in the pipeline which utilise its proprietary Permetrex™ technology for direct skin delivery.

The company announced this morning that it had completed its Investigator's Meeting for the BTX1204 clinical study.

The 12-week study will involve approximately 200 patients in dermatology clinics around the US and Australia. Participants for the study are expected to be fully recruited by the third-quarter of calendar year 2019.

The AusCann share price is up 2.4% this morning while the Botanix share price has fallen 2.3%.

Motley Fool contributor Cale Kalinowski has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

These ASX 200 shares could rise 20% to 50%

Big returns could be on the cards for owners of these shares according to analysts.

Read more »

rising gold share price represented by a green arrow on piles of gold block
Share Gainers

Here are the top 10 ASX 200 shares today

It was a horrible way to end the trading week today for ASX investors.

Read more »

Piggy bank sinking in water symbolising a record low share price.
52-Week Lows

9 ASX 200 shares tumbling to 52-week lows today

Israel's strike on Iran on Friday dragged several ASX 200 shares to new depths.

Read more »

Female miner smiling at a mine site.
Share Gainers

Up 834% in a year, guess which ASX mining stock is hitting new all-time highs today

The ASX mining stock has gone from strength to strength over the past year.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why COG, Karoon Energy, Netwealth, and Pilbara Minerals shares are dropping today

These ASX shares are ending the week deep in the red. But why?

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Fiducian Group, Northern Star, Paradigm, and Santos shares are charging higher

These shares are avoiding the market selloff.

Read more »

Dollar sign in yellow with a red falling arrow in front of a graph, symbolising a falling share price.
Share Market News

Why did the ASX 200 just sink to new 2-month lows on Friday?

It’s been a rocky week for the ASX 200. But why?

Read more »